3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
358
Precursor Cell Lymphoblastic Leukemia-Lymphoma
164
Leukemia
160
Lymphoma
109
Myelodysplastic Syndromes
74
Lymphoma, Non-Hodgkin
66
Lymphoma, Large B-Cell, Diffuse
61
Lymphoma, Mantle-Cell
59
Burkitt Lymphoma
58
Recurrence
56
Congenital Abnormalities
44
Leukemia, Monocytic, Acute
39
Lymphoma, Follicular
37
Hodgkin Disease
35
Leukemia, Myelomonocytic, Acute
34
Leukemia, Erythroblastic, Acute
34
Leukemia, Megakaryoblastic, Acute
32
Blast Crisis
29
Lymphoma, Large-Cell, Immunoblastic
27
Leukemia, Myelomonocytic, Chronic
26
Leukemia, Lymphocytic, Chronic, B-Cell
26
Leukemia, Biphenotypic, Acute
26
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
24
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
19
Lymphoma, B-Cell, Marginal Zone
19
Anemia, Refractory, with Excess of Blasts
19
Myeloproliferative Disorders
17
Lymphoma, B-Cell
17
Leukemia, Myeloid, Accelerated Phase
16
Neoplasm, Residual
15
Interventions
Thrombopoietin
3
eltrombopag
2
avatrombopag
1
Cytarabine
1
Cyclophosphamide
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Jacobs syndrome
×
Cytarabine
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts